AEON.AMEXAeon Biopharma, INC
10-K/A: AEON Biopharma Amends Annual Report to Include Omitted Corporate Governance Documents
Sentiment:
Annual Report Amendment
AEON Biopharma, Inc. has filed an amendment to its 2024 Annual Report on Form 10-K to include inadvertently omitted corporate governance documents, specifically related to its Certificate of Incorporation and Bylaws, without altering any financial or other previously reported information.
Summary
- AEON Biopharma, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The primary purpose of this amendment is to supplement Item 15(b) of Part IV of the Original Filing by including Exhibit 3.1.1 (Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation) and Exhibit 3.2.1 (Amendment to Amended and Restated Bylaws), which were inadvertently omitted.
- Additionally, Exhibit 4.5, 'Description of the Company’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934,' has been updated to reflect the revised quorum requirement for shareholder meetings, as effected by the Bylaws Amendment.
- The amendment explicitly states that no changes have been made to the financial or other information contained in the Original Filing, and it does not reflect events subsequent to the Original Filing Date of March 24, 2025.
- The company's Class A common stock has a par value of $0.0001 per share and is listed on the NYSE American under the symbol AEON.
- As of March 21, 2025, there were 10,532,802 shares of Class A common stock outstanding.
- The aggregate market value of voting and non-voting common equity held by non-affiliates was approximately $17.0 million as of the last business day of the most recently completed second fiscal quarter.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is an administrative filing to correct omissions in a previous report, with no new financial or operational information provided. It reflects compliance and correction rather than performance.
Positives
- The company is proactively addressing and correcting prior omissions in its regulatory filings, demonstrating commitment to compliance.
- The amendment clarifies and formalizes corporate governance documents, including the Certificate of Incorporation and Bylaws, which provides transparency to shareholders.
Negatives
- The initial omission of key corporate governance exhibits in the original 10-K filing indicates a potential administrative oversight.
Risks
- The Board's ability to issue preferred stock without stockholder approval could adversely affect the voting power and other rights of common stockholders and may have anti-takeover effects.
- Exclusive forum provisions in the certificate of incorporation may limit stockholders' ability to litigate disputes in a preferred judicial forum, potentially discouraging lawsuits against the company or its management.
- Anti-takeover provisions, such as a classified board, removal of directors only with cause by a two-thirds vote, and restrictions on calling special meetings, could make it more difficult for stockholders to replace the Board or for another party to gain control of the company.
- Delaware General Corporation Law (DGCL) Section 203 imposes restrictions on business combinations with interested stockholders, which could delay or prevent changes in control.
Future Outlook
This amendment does not contain any forward-looking statements or guidance, as it explicitly states that it does not reflect events that may have occurred subsequent to the Original Filing Date.
Management Comments
- Robert Bancroft, President and Chief Executive Officer, certified that, based on his knowledge, this Amendment No. 1 to the Annual Report on Form 10-K does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made not misleading.
- Jennifer Sy, Chief Accounting Officer, certified that, based on her knowledge, this Amendment No. 1 to the Annual Report on Form 10-K does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made not misleading.
Industry Context
This filing is an administrative amendment to a previously filed annual report, focusing solely on correcting exhibit omissions and updating corporate governance details. It does not provide new information related to broader industry trends, competitive landscape, or the company's operational performance within the biopharmaceutical sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Exhibit Inclusion | Inclusion of Exhibit 3.1.1, the Company's Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation, which was inadvertently omitted in the Original Filing. | NA | Formalizes and makes publicly available the latest version of the company's foundational corporate charter document. |
| Exhibit Inclusion | Inclusion of Exhibit 3.2.1, the Company's Amendment to Amended and Restated Bylaws, which was inadvertently omitted in the Original Filing. | NA | Formalizes and makes publicly available the latest version of the company's internal operating rules and procedures. |
| Bylaws Amendment | Update to Exhibit 4.5, Description of the Company's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, to update the description of the quorum requirement for shareholder meetings, which was effected by the Bylaws Amendment. | NA | Clarifies the minimum percentage of voting power required for shareholder meetings, set at 33.34%, which can impact the ease of conducting shareholder business. |
| Anti-Takeover Provisions | The certificate of incorporation and bylaws include provisions such as the ability for the Board to issue preferred stock, a classified board with three-year terms, removal of directors only with cause by a two-thirds vote, and restrictions on calling special meetings. | NA | These provisions are designed to discourage hostile takeovers and make it more difficult for stockholders to change the composition of the board or effect a change in management, potentially reducing shareholder influence. |
| Exclusive Jurisdiction | The certificate of incorporation designates the Delaware Court of Chancery (or other Delaware state/federal courts) as the sole and exclusive forum for certain corporate actions, and United States federal district courts for Securities Act claims. | NA | May limit stockholders' ability to choose a preferred judicial forum for disputes, potentially increasing litigation costs for stockholders. |
Related Party Transactions
- The exhibit list references a License and Supply Agreement and subsequent amendments with Daewoong Pharmaceutical Co., LTD., and Senior Secured Convertible Notes with Daewoong Pharmaceutical Co., LTD., indicating ongoing business relationships with a related party.
Stakeholder Impact
- Shareholders: The clarification of corporate governance documents, including quorum requirements and anti-takeover provisions, directly impacts shareholder rights and their ability to influence corporate decisions. The market value and shares outstanding information provides context for their investment.
- Regulatory Bodies: The filing demonstrates the company's adherence to SEC reporting requirements by correcting prior omissions.
Next Steps
- This Amendment should be read in conjunction with the Original Filing and the Company's other filings with the SEC for a complete understanding of the company's disclosures.
Key Dates
| Date | Description |
|---|---|
| 2019-12-20 | Date of License and Supply Agreement between Daewoong Pharmaceutical Co., LTD. and AEON Biopharma, Inc. |
| 2020-01-30 | Date of Consulting Agreement between AEON Biopharma, Inc. and Eric Carter, M.D., and its first amendment. |
| 2020-09-30 | Date of second amendment to Consulting Agreement between AEON Biopharma, Inc. and Eric Carter, M.D. |
| 2021-02-08 | Date of Warrant Agreement between Priveterra Acquisition Corp. and Continental Stock Transfer & Trust Company. |
| 2021-06-21 | Date of Settlement and License Agreement between AEON Biopharma, Inc. and Medytox, Inc. |
| 2022-05-05 | Date of Amendment to Settlement and License Agreement between AEON Biopharma, Inc. and Medytox, Inc. |
| 2022-07-29 | Date of Amendment to License and Supply Agreement between Daewoong Pharmaceutical Co., LTD. and AEON Biopharma, Inc. |
| 2022-12-12 | Date of Business Combination Agreement between Priveterra Acquisition Corp., Priveterra Merger Sub, Inc. and AEON Biopharma, Inc., and Sponsor Support Agreement. |
| 2023-01-08 | Date of Second Amendment to the License and Supply Agreement between AEON Biopharma, Inc. and Daewoong Pharmaceutical Co., Ltd. |
| 2023-04-24 | Date of Third Amendment to License and Supply Agreement by and between Daewoong Pharmaceutical Co. |
| 2023-04-27 | Date of Amendment No. 1 to Business Combination Agreement and Amendment No. 1 to Sponsor Support Agreement. |
| 2023-07-21 | Date of Amended and Restated Registration Rights Agreement. |
| 2023-07-27 | Date of filing of Form 8-K related to Third Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws, and various incentive plans and employment agreements. |
| 2023-11-24 | Date of filing of Form S-1/A related to Sponsor Support Agreement. |
| 2024-03-18 | Date of Termination Agreements with ACM ARRT J LLC and Polar Multi-Strategy Fund. |
| 2024-03-19 | Date of Subscription Agreement, Security Agreement, Guaranty, and Fourth Amendment to License and Supply Agreement with Daewoong Pharmaceutical Co., LTD. |
| 2024-03-24 | Original Filing Date of the Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 2024-03-28 | Date of Senior Secured Convertible Note with Daewoong Pharmaceutical Co., LTD. |
| 2024-03-29 | Date of filing of Form 10-K related to Specimen Warrant Certificate and Policy for Recovery of Erroneously Awarded Compensation. |
| 2024-04-02 | Date of filing of Form S-1/A related to 2023 Employee Stock Purchase Plan and amendments to License and Supply Agreement. |
| 2024-04-17 | Date of Senior Secured Convertible Note with Daewoong Pharmaceutical Co., LTD. |
| 2024-12-20 | Date of Amendment to Amended and Restated Bylaws of AEON Biopharma, Inc. |
| 2024-12-31 | Fiscal year end date for the Annual Report on Form 10-K. |
| 2025-02-24 | Date of filing of Form 8-K related to Certificate of Amendment of Third Amended and Restated Certificate of Incorporation. |
| 2025-03-21 | Date as of which 10,532,802 shares of Class A common stock were outstanding. |
| 2025-06-11 | Date of filing of this Amendment No. 1 on Form 10-K/A. |
Keywords
SEC filing, 10-K/A, amendment, corporate governance, bylaws, certificate of incorporation, quorum requirement, AEON Biopharma, annual report, exhibits, stockholders, anti-takeover provisions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.